利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

77 条记录 (耗时 0.027 秒)

    Biologically Active Peptides
    9.
    发明申请
    Biologically Active Peptides 有权
    生物活性肽

    公开(公告)号：US20120077749A1

    公开(公告)日：2012-03-29

    申请号：US13238751

    申请日：2011-09-21

    申请人： Friedrich Scheiflinger ,  Michael Dockal

    发明人： Friedrich Scheiflinger ,  Michael Dockal

    IPC分类号： A61K38/08 ,  C07K7/64 ,  A61P7/04 ,  C07K7/08 ,  C07K1/04 ,  C07K7/06 ,  C07K2/00

    CPC分类号： C07K7/06 ,  A61K38/00 ,  C07K1/04 ,  C07K7/08 ,  C07K14/755 ,  Y02P20/55

    摘要： A peptide or peptide derivative comprising: (i) WDLYFEIVW;(SEQ ID NO: 1) (ii) a variant amino acid sequence comprising one, two, three or four L-amino acid substitutions in WDLYFEIVW (SEQ ID NO: 1); or (iii) the retro-inverso variant of the peptide or peptide derivative of either one of parts (i) and (ii), wherein said peptide or peptide derivative has procoagulant activity. A peptide or peptide derivative comprising: (i) an amino acid sequence comprising imfwydcye; or (ii) a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye, wherein said peptide or peptide derivative has procoagulant activity.

    摘要翻译： 一种肽或肽衍生物，其包含：（i）WDLYFEIVW; （SEQ ID NO：1）（ii）在WDLYFEIVW（SEQ ID NO：1）中包含一个，两个，三个或四个L-氨基酸取代的变体氨基酸序列; 或（iii）部分（i）和（ii）中任一项的肽或肽衍生物的逆转型变体，其中所述肽或肽衍生物具有促凝活性。 一种肽或肽衍生物，其包含：（i）包含成纤维细胞的氨基酸序列; 或（ii）在成纤维细胞中包含一个，两个，三个，四个，五个或六个氨基酸取代的变体氨基酸序列，其中所述肽或肽衍生物具有促凝活性。

    Methods for Treating Bleeding Disorders
    10.
    发明申请
    Methods for Treating Bleeding Disorders 有权
    治疗出血障碍的方法

    公开(公告)号：US20110110921A1

    公开(公告)日：2011-05-12

    申请号：US13002501

    申请日：2009-08-21

    申请人： Michael Dockal ,  Friedrich Scheiflinger ,  Peter Turecek

    发明人： Michael Dockal ,  Friedrich Scheiflinger ,  Peter Turecek

    IPC分类号： A61K31/737 ,  A61K31/727 ,  A61K38/48 ,  A61K38/37 ,  A61K38/36 ,  C12Q1/56 ,  A61P7/04

    CPC分类号： A61K31/737 ,  A61K31/727 ,  A61K38/36 ,  A61K38/366 ,  A61K38/37 ,  A61K38/4846 ,  A61K38/4853 ,  A61K45/06 ,  G01N33/86 ,  A61K2300/00

    摘要： A method of factor XI-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject. A method of factor XI-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising: (i) selecting a subject that is not deficient for factor XI; and (ii) administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject, wherein the NASP enhances blood coagulation in a factor XI-dependent manner. A method of identifying a non-anticoagulant sulfated polysaccharide (NASP) which is capable of enhancing blood coagulation in dependence on FXI, the method comprising: a) combining a blood or plasma sample comprising activation competent FXI with a composition comprising a sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample; b) combining a corresponding blood or plasma sample deficient in activation competent FXI with a composition comprising the sulfated polysaccharide and measuring the clotting or thrombin generation parameters of the blood or plasma sample; and c) comparing the clotting or thrombin generation parameters of the blood or plasma samples as determined in steps (a) and (b) with each other, wherein a decrease in the clotting time of the blood sample or an increase in peak thrombin or decrease in peak time of the plasma sample comprising activation competent FXI compared to the clotting time of the blood sample or peak thrombin or peak time of the plasma sample deficient in activation competent FXI is indicative of a NASP which is capable of enhancing blood coagulation in dependence on FXI.

    摘要翻译： 一种需要增强血液凝固的受试者中因子XI依赖性血液凝固增强的方法，包括向受试者施用治疗有效量的包含非抗凝血硫酸多糖（NASP）的组合物。 一种需要增强血液凝固的受试者中因子XI依赖性血液凝固增强的方法，包括：（i）选择不是因子XI缺陷的受试者; 和（ii）向所述受试者施用治疗有效量的包含非抗凝血硫酸多糖（NASP）的组合物，其中所述NASP以因子XI依赖性方式增强血液凝固。 一种鉴定能够根据FXI增强血液凝固的非抗凝血硫酸多糖（NASP）的方法，所述方法包括：a）将包含活化能力的FXI的血液或血浆样品与包含硫酸化多糖的组合物和测量 血液或血浆样品的凝血酶或凝血酶产生参数; b）将活化受体FXI中缺乏的相应血液或血浆样品与包含硫酸化多糖的组合物结合并测量血液或血浆样品的凝血酶或凝血酶产生参数; 和c）比较步骤（a）和（b）中确定的血液或血浆样品的凝血酶或凝血酶产生参数，其中血液样品的凝血时间的降低或峰值凝血酶的增加或减少 在包含活化能力的FXI的血浆样品的峰值时间与血液样品的凝血时间或峰值凝血酶相比，或者在活化能力FXI中缺乏的血浆样品的峰值时间指示NASP，其能够依赖于 FXI。